NEW YORK (GenomeWeb) – Canadian firm LexaGene Holdings said today that it has closed a non-brokered private placement under which it raised gross proceeds of about C$2 million ($1.5 million).

The company sold 6.7 million units of common stock at C$.30 per unit. Each unit consisted of one common share and one common share purchase warrant, which entitles the holder to acquire an additional common share for C$.60 per share within a three-year period. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.